Rua Life Sciences Share Discussion Threads

[mikeh30] 11/10/2021 21:27

https://m.marketscreener.com/quote/stock/RUA-LIFE-SCIENCES-PLC-4004191/company/Is that another AMATI fund that took Walker crips stake ?

[greedy rooster] 11/10/2021 12:41

Quiet accumulation continues - good to see.

[homebrewruss] 08/10/2021 09:10

Best buy £1K then :)

[someuwin] 08/10/2021 09:04

Can buy £1k online. But not £2k.

[coolhandfluke] 08/10/2021 08:34

Thank you GR. you just reminded me why I got back in.

[greedy rooster] 08/10/2021 08:30

Once you sign-up to the medical, societal and commercial benefits of non-biogenic devices, it seems logical that they move from being disruptive towards being the norm. We know RUA has a 'long pipeline' of devices in R&D, and their IP covers a range of potential uses in markets that haven't changed for decades. We're all waiting for the successful first launch, but this paves the way for so many different opportunities that should make the current price insignificant, all underpinned by the sleepy jewel in the crown, Elasteon. And this is the side show to the heart valve project!

[langland] 07/10/2021 17:44

That makes sense, bones. Thank you. ED has been caught out before with errors or not making things clear.

[langland] 07/10/2021 16:05

The 40k print/trade was not a sale....just me switching some stuff around.

[bones] 07/10/2021 15:48

On a further read of the ED bumph on the webinar, I can see that the phrase “ahead of” probably applies to the “in vivo testing (that has already been done) ahead of the 510k submission” rather than the “3/11 seminar taking place ahead of the 510k submission”.

It’s a failing in the published communication and I feel these organisations need to proof read their releases for clarity to prevent unnecessary confusion!

[bones] 07/10/2021 08:54

So, in summary, ED have given the impression of a submission after 3rd November when nothing in the RNS’s has suggested such a timeline. That’s the point Unionhall raised and I agree with him on that. It’s an observation, that is all.

I also agree with GR that these are exciting times.

[mikeh30] 07/10/2021 08:41

They've just taken snippet from the RNS RUA is very excited by the observations from the 'in vivo' testing and believes this could become a potentially seminal paper on the future direction of surgical graft implantation

[greedy rooster] 07/10/2021 08:32

There is nothing in the last update to suggest that more in Vivo testing will be carried out ahead of the submission to FDA. Everything is on track with an exciting couple of months ahead.

[bones] 06/10/2021 22:17

That’s how it reads to me too, unionhall, but I wonder if there is some mistake in the messaging by Equity Development in the summary here because that kind of delay seems not to have been flagged by RUA, although they haven’t committed to a specific date as such.

I was expecting the submission of the 510k to be timed around the EACTS conference.

[unionhall] 06/10/2021 21:10

"...The event will be an opportunity for investors to hear directly from the company about the Vascular graft range in detail, and discuss learnings from the October annual meeting of the European Association of Cardiothoracic Surgeons (EACTS) and latest 'in vivo' testing developments ahead of their 510k submission..."


Slightly confused by the wording in the final clause.....

Does this mean the 510k submission will not have been made by November 2nd ?

[coolhandfluke] 06/10/2021 13:21

Back in today in a small way (no money left)?. I wondered whether today's news story about a potential pig cull might give RUA share price a boost.

[spurious] 05/10/2021 14:02

Cheers Bones

[bones] 05/10/2021 13:57

Nice work Spurious.

The date for the Equity Development presentation is 3rd November:

[wageslave] 05/10/2021 09:45

#RUA Upcoming Catalysts;Q4... - FDA 510k submission - EACTS conference (surgeon carrying out assessment of graft) - Feedback following conference Q1...- FDA approval - Launch of product - Confirmation of distribution partnersQ2...- Significant scaling up of product

[bones] 04/10/2021 14:38

The EACTS conference is next week (13th-16th October) at which RUA have said they are having a scientific paper presented concerning the Elast-Eon grafts trials and the associated findings of interest.



Today, Equity Development said (via a Twitter post in response to an enquiry about the EACTS event):

”….. We are planning on hosting an event so the management can report back on EACTS conference, early November.”

[bones] 28/9/2021 16:13

Worth a reread of this from last year, just before the name change from Aortech:



A lot of background on the heart valve project. The concluding paragraphs from Chairman Bill Brown were significant:

“Take-out values have been US$300-500mln,” he points out. “What we’ve got is substantially more disruptive.

“It is a massive opportunity, which if we get it right, will be fantastic for our shareholders. But if we don’t get it right, we still have a valuable exciting business.”

[bones] 28/9/2021 16:03

Thanks. Translates to a 3 bagger over 4 years with the share issues but not always an easy ride! But it’s a great team up there in Scotland!

[nimbo1] 28/9/2021 15:51

thanks! look forward to doing deeper dd

Congrats on your holding since £2m mc : )

[bones] 28/9/2021 15:44

Welcome, nimbo1. I have been in this since it was £2M m/cap with 5M shares in issue to now, £33M m/cap with 22M shares in issue. I still love the story here. The management have been resolute in the long term aims and the next six months could be pivotal. Yet even that progress pales into insignificance compared to the heart valve project. That could get a turbo boost however once Elast-Eon is given an overdue blast of limelight via the grafts commercialisation.